Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)
:6990
Want to see HK:6990 full AI Analyst Report?
Total Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$100.91B. The enterprise value is HK$8.76B.
Market CapHK$100.91B
Enterprise ValueHK$8.76B
Share Statistics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 170,984,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding170,984,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -9.09%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.09%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee1.01M
Profits Per Employee-173.98K
Employee Count2,045
Asset Turnover0.34
Inventory Turnover2.40
Valuation Ratios
The current PE Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is ―. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s PEG ratio is -0.79.
PE Ratio―
PS Ratio5.66
PB Ratio2.39
Price to Fair Value2.39
Price to FCF-38.01
Price to Operating Cash Flow187.95
PEG Ratio-0.79
Income Statement
In the last 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H had revenue of 2.06B and earned -381.97M in profits. Earnings per share was -1.66.
Revenue2.06B
Gross Profit1.48B
Operating Income-466.19M
Pretax Income-355.78M
Net Income-381.97M
EBITDA-249.23M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was 66.13M and capital expenditures -59.61M, giving a free cash flow of 6.52M billion.
Operating Cash Flow66.13M
Free Cash Flow6.52M
Free Cash Flow per Share0.04
Dividends & Yields
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change27.83%
50-Day Moving Average443.09
200-Day Moving Average446.29
Relative Strength Index (RSI)49.56
Average Volume (3m)641.47K
Important Dates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H upcoming earnings date is Aug 24, 2026, TBA (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateAug 24, 2026
Ex-Dividend Date―
Financial Position
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H as a current ratio of 5.13, with Debt / Equity ratio of 1.63%
Current Ratio5.13
Quick Ratio4.89
Debt to Market Cap<0.01
Net Debt to EBITDA13.01
Interest Coverage Ratio-75.71
Taxes
In the past 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has paid 26.19M in taxes.
Income Tax26.19M
Effective Tax Rate-0.07
Enterprise Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H EV to EBITDA ratio is -33.74, with an EV/FCF ratio of -27.43.
EV to Sales4.09
EV to EBITDA-33.74
EV to Free Cash Flow-27.43
EV to Operating Cash Flow-46.63
Balance Sheet
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has HK$4.56B in cash and marketable securities with HK$88.44M in debt, giving a net cash position of HK$4.47B billion.
Cash & Marketable SecuritiesHK$4.56B
Total DebtHK$88.44M
Net CashHK$4.47B
Net Cash Per ShareHK$26.15
Tangible Book Value Per ShareHK$21.11
Margins
Gross margin is 73.17%, with operating margin of -22.65%, and net profit margin of -18.56%.
Gross Margin73.17%
Operating Margin-22.65%
Pretax Margin-17.29%
Net Profit Margin-18.56%
EBITDA Margin-12.11%
EBIT Margin-16.99%
Analyst Forecast
The average price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is HK$561.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$561.61
Price Target Upside8.00% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast6.59%
EPS Growth Forecast-46.41%